RIDGEFIELD, Conn., Oct. 12 /PRNewswire/ -- Boehringer Ingelheim today announced that the company has been awarded top honors by Science as the world’s most respected biopharmaceutical employer. Science’s annual survey of more than 470 Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries. Respondents to the web-based survey are asked to rate companies based on 23 driving characteristics, including corporate image, leadership and direction, financial strength, company culture, work/life balance, compensation, and benefits, as well as being easily adaptable to change and having a thriving research-driven environment.
“We are very pleased to be recognized as a global leader in the pharmaceutical industry by Science,” said J. Martin Carroll, president and chief executive officer of Boehringer Ingelheim Corporation. “It is especially gratifying to receive this honor knowing it is a measurement of corporate reputation among both our employees and the employees of our competitors. This international recognition truly signifies that Boehringer Ingelheim is an Employer of Choice in the United States and around the world.”
Over the past few years that Science has carried out this survey, Boehringer Ingelheim has climbed up in ranking, from 8th place in 2005 to second place last year. This year, Boehringer Ingelheim reached the top ranking, recognizing the company’s strong commitment to innovative thinking throughout the product pipeline, from the laboratory to the marketplace, while establishing an excellent working environment.
Like Science’s 2006 ranking of biopharma employers, the 2007 survey sought to identify the companies with the best reputations as employers, based on 3,157 survey responses from readers of Science and other respondents in industry. Twenty-nine percent of respondents came from outside of the United States, primarily Western Europe, and more than 90 percent worked in private industry.
The rankings, determined from a study conducted by an independent research firm commissioned by the business office of the journal, will appear in a special business supplement of the 12 October 2007 issue. Survey responses were analyzed by Senn-Delaney Culture
Diagnostics & Measurement, which used a mathematical process to assign a unique score to rate the companies’ employer reputation. Each company received a ranking, for example, on the basis of whether it treats its employees with respect, whether its work-culture values align with employees’ personal values, and other factors.
For the complete business office supplement with individual company rankings, visit http://sciencecareers.sciencemag.org/career_development/previous_issues/articl es/2007_10_12/science_opms_r0700041.
About the American Association for the Advancement of Science (AAAS)
The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society, and publisher of the journal, Science (www.sciencemag.org). AAAS was founded in 1848, and includes some 262 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of one million. The non-profit AAAS (www.aaas.org) is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy, international programs, science education, and more.
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. For more information, please visit http://us.boehringer-ingelheim.com.
CONTACT: Marybeth C. McGuire, Associate Director, Corporate
Communications, of Boehringer Ingelheim Pharmaceuticals, Inc.,
+1-203-798-4801 or mmcguire@rdg.boehringer-ingelheim.com
Web site: http://us.boehringer-ingelheim.com/
http://www.aaas.org/
http://www.sciencemag.org/
